Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.

e17560 Background: There are approximately 436,000 survivors of head and neck squamous cell carcinoma (HNSCC) in the U.S. Toxicities related to definitive chemoradiation or radiation therapy can persist for many years, with some toxicities not presenting clinically until five or more years after definitive treatment. Long-term management of late radiotherapy effects is thus warranted. Methods: This retrospective chart review has three aims: (1) comprehensively assess overall late effects of definitive radiation and chemoradiation; (2) compare treatment-related toxicities between definitive radiation and chemoradiation; and (3) compare treatment-related toxicities between patients with TNM stage T1/T2 tumors to T3/T4 tumors. Late term effects were assessed using 17 toxicity categories including xerostomia, dysphagia, and neck fibrosis. HNSCC patients included in the study were those seen by a single practitioner for follow-up of definitive radiation or chemoradiation, without a history of surgical intervention to the primary site, between June 2017 and June 2018 (N = 49). Results: The median time from the end of treatment to the most recent follow-up was 8.53 years (1.17-24.08 years). In the total cohort, the most common late effect was xerostomia (78%, N = 38), followed by dysphagia (43%, N = 21), and neck fibrosis (27%, N = 13). For the majority of toxicity categories (11 of 17), the cohort that received definitive chemoradiation had higher rates of toxicity than the cohort that received definitive radiation alone. Additionally, for the majority of toxicity categories (10 of 17), the cohort of T3/T4 tumors had higher rates of long-term toxicity than the cohort of T1/T2 tumors. Conclusions: Although the patient population in this study has excellent locoregional control after definitive radiation or chemoradiation, the majority of patients suffer from long-term treatment-related toxicities. Long-term follow up care is needed to manage the late effects of radiotherapy that can develop and persist for years after treatment completion.

Download Full-text

O14 Phase II study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data

Oral Oncology Supplement ◽

10.1016/s1744-7895(07)70031-7 ◽

2007 ◽

Vol 2 (1) ◽

pp. 55

Author(s):

P. Specenier ◽

D. Van den Weyngaert ◽

C. Van Laer ◽

J. Weyzer ◽

J. Van den Brande ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Concurrent Radiotherapy ◽

Long Term Follow Up

Download Full-text

Prevalence of Cachexia After Curative Cisplatin-Based Concurrent Chemoradiation in Head and Neck Cancers

10.21203/rs.3.rs-447761/v1 ◽

2021 ◽

Author(s):

Willian das Neves Silva ◽

Thomas Giollo Rivelli ◽

Eduardo Furquim Simao ◽

Marco Aurelio Vamondes Kulcsar ◽

Gilberto de Castro Junior

Keyword(s):

Squamous Cell Carcinoma ◽

Muscle Strength ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Locally Advanced ◽

Neck Squamous Cell Carcinoma ◽

Curative Intent ◽

Long Term Follow Up

Abstract PurposeWe determine the frequency of cachexia among head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiation with curative intent and presenting no evidence of disease. MethodsConsecutive patients were included from January 2014 to February 2017. Participants were over 18 y.o. and diagnosed with head and neck squamous cell carcinomas previously treated with definitive or adjuvant chemoradiation. Eligible patients were in regular follow-up for at least 2 years, with no evidence of disease. Body weight, height, mid-arm muscle circumference, muscle strength, and nutritional status were measured, and blood tests were obtained. The main outcome was the presence of cachexia, and self-reported dysphagia. Results120 patients were included, 73% were male, and age was 59 y.o. (range, 21–78). The most common primary site was oropharynx (42%). Median follow-up was 42 mo. (range, 24–125 mo.). Most patients presented locally advanced disease at diagnosis: 73% T3-T4 and 72% N+. Dysphagia was a major complaint (73%). Cachexia was diagnosed in 23 (20.7%) and 10 (8.6%) patients according to Fearon and Evans criteria, respectively. Cachectic patients presented lower mid-arm muscle circumference (p < 0.05). In addition, lower muscle strength levels (p<0.05) were found among cachectic patients according to Evans criteria, and there was an association between the presence of dysphagia and the diagnosis of cachexia. ConclusionsHead and neck squamous cell carcinoma patients with no evidence of disease frequently present cachexia after chemoradiation in a long-term follow-up. More effective preventive and therapeutic strategies for cachexia are required in this scenario.

Download Full-text

Effect of coronavirus disease 2019 on recurrences and follow up of head and neck squamous cell carcinoma

The Journal of Laryngology & Otology ◽

10.1017/s0022215121000918 ◽

2021 ◽

pp. 1-4

Author(s):

E Kytö ◽

E Haapio ◽

I Kinnunen ◽

H Irjala

Keyword(s):

Squamous Cell Carcinoma ◽

Prospective Study ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

One Year ◽

Diagnostic Delays

Abstract Objective This prospective study aimed to evaluate possible diagnostic delays in head and neck squamous cell carcinoma recurrences due to the changed follow-up protocol during the coronavirus disease 2019 pandemic. Methods The follow-up appointments of head and neck squamous cell carcinoma patients treated more than one year prior to the pandemic were changed to telephone appointments in order to reduce physical visits to the hospital. All contacts, reasons for contact and recurrent cancers were recorded. Results There were 17 recurrences during a seven-month study period among 178 patients treated in the previous year (10 per cent); 14 of these recurrences occurred in patients whose treatment had ended less than one year previously and 3 occurred more than one year after treatment had ended. There was no delay in diagnoses of recurrent tumours or treatment despite reduced visits because of the coronavirus disease 2019 pandemic. Conclusion According to our analyses, no delay was caused in the diagnoses of recurrent diseases. Follow up by telephone or telemedicine can be considered as part of the follow-up protocol one year after the treatment of head and neck squamous cell carcinoma when necessary.

Download Full-text